short acting glp 1 agonists GLP-1 and Diabetes Mellitus A Comprehensive Review of the
Description
Retatrutide NAFLD: phase 2 trial results in subset of patients with obesity and NAFLD
These findings support semaglutide 2.4 mg as an effective therapeutic option for weight and fat mass reduction while preserving, or potentially improving, muscle function and metabolic health
Grandt AD, Schimiczek M, Beglinger C, Layer P, Goebell H, Eysselein VE, et al
June 2, 2024
